DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer

References

• Cortazar P , ZhangL, UntchMet al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet384(9938), 164–172 (2014).
   PubMed Web of Science ®Google Scholar
• Azim HA , de AzambujaE, ColozzaM, BinesJ, PiccartMJ. Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann. Oncol.22(9), 1939–1947 (2011).
   PubMed Web of Science ®Google Scholar
• Carey LA , BerryDA, CirrincioneCTet al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J. Clin. Oncol.34(6), 542–549 (2016).
   PubMed Web of Science ®Google Scholar
• Parker JS , MullinsM, CheangMCUet al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol.27(8), 1160–1167 (2009).
   PubMed Web of Science ®Google Scholar
• Brandão M , CaparicaR, MalorniL, PratA, CareyLA, PiccartM. What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?Clin. Cancer Res.26(12), 2783–2788 (2020).
   PubMed Web of Science ®Google Scholar
• Schettini F , PascualT, ConteBet al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat. Rev.84, 101965 (2020).
   PubMed Web of Science ®Google Scholar
• Loibl S , GianniL. HER2-positive breast cancer. Lancet389(10087), 2415–2429 (2017).
   PubMed Web of Science ®Google Scholar
• Marty M , CognettiF, MaraninchiDet al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol.23(19), 4265–4274 (2005).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A , GelberRD, Piccart-GebhartMJet al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet382(9897), 1021–1028 (2013).
   PubMed Web of Science ®Google Scholar
• Viani GA , AfonsoSL, StefanoEJ, DeFendi LI, SoaresFV. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer7, 153 (2007).
   PubMed Web of Science ®Google Scholar
• von Minckwitz G , ProcterM, de AzambujaEet al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med.377(2), 122–131 (2017).
   PubMed Web of Science ®Google Scholar
• Loibl S , JassemJ, SonnenblickAet al. VP6-2022: adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up. Annal. Oncol.33(9), (2022).
   Google Scholar
• Gianni L , PienkowskiT, ImY-Het al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol.17(6), 791–800 (2016).
   PubMed Web of Science ®Google Scholar
• Schneeweiss A , ChiaS, HickishTet al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur. J. Cancer89, 27–35 (2018).
   PubMed Web of Science ®Google Scholar
• Shao Z , PangD, YangHet al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol.6(3), e193692 (2020).
   PubMed Web of Science ®Google Scholar
• Baselga J , BradburyI, EidtmannHet al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet379(9816), 633–640 (2012).
   PubMed Web of Science ®Google Scholar
• Robidoux A , TangG, RastogiPet al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol.14(12), 1183–1192 (2013).
   PubMed Web of Science ®Google Scholar
• Gianni L , BisagniG, ColleoniMet al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol.19(2), 249–256 (2018).
   PubMed Web of Science ®Google Scholar
• Guarneri V , GriguoloG, MigliettaF, ContePF, DieciMV, GirardiF. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials. ESMO Open7(2), 100433 (2022).
   PubMed Web of Science ®Google Scholar
• von Minckwitz G , HuangC-S, ManoMSet al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med.380(7), 617–628 (2019).
   PubMed Web of Science ®Google Scholar
• Prat A , CareyLA, AdamoBet al. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J. Natl Cancer Inst.106(8), (2014).
   Google Scholar
• Prat A , GuarneriV, ParéLet al. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncol.21(11), 1455–1464 (2020).
   PubMed Web of Science ®Google Scholar
• Llombart-Cussac A , CortésJ, ParéLet al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol.18(4), 545–554 (2017).
   PubMed Web of Science ®Google Scholar
• Swain SM , EwerMS, VialeGet al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann. Oncol.29(3), 646–653 (2018).
   PubMed Web of Science ®Google Scholar
• NIH. Female Breast Cancer Subtypes – Cancer Stat Facts. https://seer.cancer.gov/statfacts/html/breast-subtypes.html
   Google Scholar
• Tolaney SM , BarryWT, DangCTet al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N. Engl. J. Med.372(2), 134–141 (2015).
   PubMed Web of Science ®Google Scholar
• Bellon JR , GuoH, BarryWTet al. Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res. Treat176(2), 303–310 (2019).
   PubMed Web of Science ®Google Scholar
• Cardoso F , KyriakidesS, OhnoSet al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annal. Oncol.30(8), 1194–1220 (2019).
   PubMed Web of Science ®Google Scholar
• van Ramshorst MS , vander Voort A, van WerkhovenEDet al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol.19(12), 1630–1640 (2018).
   PubMed Web of Science ®Google Scholar
• van der Voort A , van RamshorstMS, van WerkhovenEDet al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial. JCO38(Suppl. 15), 501–501 (2020).
   Google Scholar
• Nitz UA , GluzO, ChristgenMet al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel. Annals of Oncology28(11), 2768–2772 (2017).
   PubMed Web of Science ®Google Scholar
• Pérez-García JM , GebhartG, RuizBorrego Met al. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol.22(6), 858–871 (2021).
   PubMed Web of Science ®Google Scholar
• Tan AR , ImS-A, MattarAet al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol.22(1), 85–97 (2021).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J , SousaS, CruzJet al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): a randomised, open-label phase II study. Eur. J. Cancer152, 223–232 (2021).
   PubMed Web of Science ®Google Scholar
• Allison KH , HammondMEH, DowsettMet al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J. Clin. Oncol.38(12), 1346–1366 (2020).
   PubMed Web of Science ®Google Scholar
• Symmans WF , PeintingerF, HatzisCet al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. JCO25(28), 4414–4422 (2007).
   PubMed Web of Science ®Google Scholar
• Tolaney SM , Garrett-MayerE, WhiteJet al. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. JCO39(24), 2720–2731 (2021).
   PubMed Web of Science ®Google Scholar
• Debien V , AdamV, CaparicaRet al. DECRESCENDO: de-escalation of adjuvant chemotherapy in patients with HER2+/HR−/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade. Clin. Oncol.14(Suppl. 16), TPS621 (2022).
   Google Scholar